Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.

Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.

The invention relates to a peptide isolate isolated from a biomass of protein-rich microalgae, characterized in that it comprises: soluble peptides with a molecular weight of between 1 and 20 kDa, a protein content expressed as N.6.25 of more than 95%, essentially arginine and glutamic acid.

The invention relates to a method for fractionating the components of a biomass of protein-rich microalgae of the genus Chlorella, characterized in that it comprises the following steps: providing a microalgal biomass produced by fermentation, optionally, washing the biomass so as to eliminate the interstitial soluble compounds, thermal permeabilization of the biomass at a temperature of between 50 and 150° C., preferably 100 and 150° C., for a duration of between 10 seconds and 5 minutes, preferably for a duration of between 5 seconds and 1 minute, separation between the biomass thus permeabilized and the soluble fraction by a centrifugation technique, more particularly multistage centrifugation, optionally, recovery and clarification of the soluble fraction obtained in this way by microfiltration so as to remove residual insoluble substances therefrom, separation of the preceding soluble fraction by precipitation, so as to obtain a peptide isolate and a peptide concentrate.

A process for producing an arginine-rich peptide mixture and the application thereof in cervical cancer therapy is provided. The process includes the following steps: A suspension of walnut meal and egg albumin is pretreated with ultrahigh pressure, and then digested by alkaline proteinase and papain in separated steps with the ultrasonic and microwave-assisted extraction. The peptides of interest are isolated from filtration supernatant obtained after the enzyme digestion by reversed phase high-performance liquid chromatography. By using the peptide mixture as a template, acrylic acid and methyl acrylic acid as functional monomers, triethylene glycol dimethacrylate as cross-linking agent, and isopropylthioxanthone in acetone as a photoinitiator, polymerization is induced by ultraviolet light to form a surface imprinted membrane for isolating and enriching the peptides of interest from the supernatant. The arginine content in the peptide mixture is more than 18%. The arginine-rich peptide mixture is able to strongly suppress the proliferation of human cervical cancer Hela cells. The approach is applicable to reduce the cost of production and speed up the commercialization of large-scale production.

A process for producing an arginine-rich peptide mixture and the application thereof in cervical cancer therapy is provided. The process includes the following steps: A suspension of walnut meal and egg albumin is pretreated with ultrahigh pressure, and then digested by alkaline proteinase and papain in separated steps with the ultrasonic and microwave-assisted extraction. The peptides of interest are isolated from filtration supernatant obtained after the enzyme digestion by reversed phase high-performance liquid chromatography. By using the peptide mixture as a template, acrylic acid and methyl acrylic acid as functional monomers, triethylene glycol dimethacrylate as cross-linking agent, and isopropylthioxanthone in acetone as a photoinitiator, polymerization is induced by ultraviolet light to form a surface imprinted membrane for isolating and enriching the peptides of interest from the supernatant. The arginine content in the peptide mixture is more than 18%. The arginine-rich peptide mixture is able to strongly suppress the proliferation of human cervical cancer Hela cells. The approach is applicable to reduce the cost of production and speed up the commercialization of large-scale production.

The present disclosure pertains to compositions comprising anti-VEGF proteins.

The present disclosure pertains to compositions comprising anti-VEGF proteins.

The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and/or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).